Insider Transactions in Q4 2024 at Mineralys Therapeutics, Inc. (MLYS)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.32%
|
$0
$0.54 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,026
-3.44%
|
$75,390
$15.0 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,043
+3.38%
|
$0
$0.81 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,482
-15.78%
|
$382,230
$15.03 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,482
+13.63%
|
$25,482
$1.08 P/Share
|
|
Oct 14
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,352
+3.79%
|
$5,352
$1.08 P/Share
|
|
Oct 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,271
-1.68%
|
$198,523
$13.52 P/Share
|
|
Oct 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.7%
|
$0
$0.54 P/Share
|
|
Oct 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.34%
|
$139,841
$13.57 P/Share
|